# Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

> **NCT06664125** · PHASE2 · RECRUITING · sponsor: **Jemincare** · enrollment: 50 (estimated)

## Conditions studied

- Hyperphosphatemia

## Interventions

- **DRUG:** JMKX003002 will be administered orally
- **DRUG:** Sevelamer carbonate

## Key facts

- **NCT ID:** NCT06664125
- **Lead sponsor:** Jemincare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06664125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06664125, "Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06664125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*